NASDAQ:TENXTenax Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tenax Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.28 +0.03 (+2.40 %) (As of 08/10/2020 12:01 PM ET) Add Compare Share Today's Range$1.28Now: $1.28▼$1.3150-Day Range$0.90MA: $1.08▼$1.3952-Week Range$0.25Now: $1.28▼$2.68Volume1,100 shsAverage Volume493,283 shsMarket Capitalization$12.93 millionP/E RatioN/ADividend YieldN/ABeta2.39 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Tenax Therapeutics. Previous Next 2.9 Community Rank Outperform VotesTenax Therapeutics has received 134 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTenax Therapeutics has received 97 “underperform” votes. (Add your “underperform” vote.)Community SentimentTenax Therapeutics has received 58.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote “Outperform” if you believe TENX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,450.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.02% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.66% of the stock of Tenax Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.80) to ($1.01) per share.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TENX Previous Symbol CUSIPN/A CIK34956 Webwww.tenaxthera.com Phone919-855-2100Debt Debt-to-Equity Ratio0.01 Current Ratio2.31 Quick Ratio2.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book2.29Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,390,000.00 Net MarginsN/A Return on Equity-168.82% Return on Assets-126.78%Miscellaneous Employees9 Outstanding Shares10,100,000Market Cap$12.93 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $1.28 +0.03 (+2.40 %) (As of 08/10/2020 12:01 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TENX News and Ratings via Email Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions How has Tenax Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Tenax Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TENX shares have increased by 23.1% and is now trading at $1.28. View which stocks have been most impacted by Coronavirus. When is Tenax Therapeutics' next earnings date? Tenax Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Tenax Therapeutics. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics Inc (NASDAQ:TENX) released its earnings results on Friday, May, 15th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter. View Tenax Therapeutics' earnings history. When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work? Tenax Therapeutics's stock reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split. Has Tenax Therapeutics been receiving favorable news coverage? News stories about TENX stock have been trending very positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tenax Therapeutics earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Tenax Therapeutics. Who are some of Tenax Therapeutics' key competitors? Some companies that are related to Tenax Therapeutics include AIkido Pharma (AIKI), Cleveland BioLabs (CBLI), HedgePath Pharmaceuticals (HPPI), Geovax Labs (GOVX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). View all competitors. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX), Bank of Hawaii (BOH), Idera Pharmaceuticals (IDRA), Gilead Sciences (GILD), InterDigital Wireless (IDCC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Novavax (NVAX) and Verastem (VSTM). Who are Tenax Therapeutics' key executives? Tenax Therapeutics' management team includes the following people: Mr. Anthony A. DiTonno, CEO & Director (Age 71)Mr. Michael B. Jebsen, Pres & CFO (Age 48)Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.Maria Isabel Tomargo, Assistant VP of Marketing & SalesMr. Robert F. Diegelmann, Head of New Wound Care Division What is Tenax Therapeutics' stock symbol? Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX." Who are Tenax Therapeutics' major shareholders? Tenax Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.52%) and Virtu Financial LLC (0.45%). View institutional ownership trends for Tenax Therapeutics. Which institutional investors are buying Tenax Therapeutics stock? TENX stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and Virtu Financial LLC. View insider buying and selling activity for Tenax Therapeutics. How do I buy shares of Tenax Therapeutics? Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Tenax Therapeutics' stock price today? One share of TENX stock can currently be purchased for approximately $1.28. How big of a company is Tenax Therapeutics? Tenax Therapeutics has a market capitalization of $12.93 million. Tenax Therapeutics employs 9 workers across the globe. What is Tenax Therapeutics' official website? The official website for Tenax Therapeutics is www.tenaxthera.com. How can I contact Tenax Therapeutics? Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
